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expected, TX is the most convenient treatment, as regards cost-
effectiveness estimates. PD is also preferred to HD. National
Health System authorities should, therefore, favor PD over HD.
If that is the case, a Budget Impact Analysis would help to assess
to which extent such approach would be worthy.
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OBJECTIVES: Health economic analyses are used routinely to
evaluate a number of types of health care interventions and are
required for all new pharmaceuticals by many national and
regional health authorities. These analyses assess the implications
of projected outcomes and costs of a new drug treatment and are
often used as a tool to guide decisions about pharmaceutical
development and consumption. As an illustrative example, an
overview of the components and construction of an economic
model is presented here using the costs and outcomes associated
with fesoterodine (FESO), a new antimuscarinic that has been
shown to be safe, tolerable, and effective for the management of
overactive bladder (OAB) in adults. METHODS: Economic
evaluations comparatively assess the costs in terms of resources
consumed and consequences of drug (eg, FESO therapy). The
type of analysis illustrated is a cost utility analysis (CUA), which
focuses particular attention on the costs and incremental health
improvement attributable to fesoterodine. The costs of treatment
are measured in monetary units and include medical costs pur-
chased by the health care system, including physician visits,
diagnostic and laboratory tests, hospitalizations, and so forth.
Other costs consist of the patient’s out-of-pocket expenses for
goods and services outside of the medical sector, such as incon-
tinence pads. Unpurchased resources consumed by patients with
OAB include lost productivity while at work or lost time from
work owing to the condition. Health improvement due to FESO
is measured by quality-adjusted life years (QALYs, pronounced
“qualies”). The QALY is a measure of health outcome, which
assigns to each period of time a weight, ranging from zero (death)
to one (perfect health) corresponding to the quality of life during
that period. The need for incorporating QALYs, rather than life
years or expectancy, is due to the observation that many medical
interventions, such as those for OAB, are not associated with
premature death but with changes in morbidity and quality of
life. Finally, the central outcome in a CUA is the cost utility ratio,
the difference in the costs of the 2 alternatives divided by the
difference in QALYs. This ratio is essentially the cost of an
additional QALY when using 1 intervention compared with an
alternative. RESULTS: A CUA was created examining the costs
and beneﬁts of FESO demonstrated in a 12-week, randomized,
double-blind, placebo- and active-controlled clinical trial. Com-
parators were FESO 4 mg/d, FESO 8 mg/d, extended-release
tolterodine 4 mg/d (TOL), and solifenacin (SOL). SOL was not
included in the clinical trial, therefore efﬁcacy data were obtained
from the published literature. Medical costs of OAB (antimusca-
rinic drugs, physician visits, laboratory tests, and OAB-related
comorbidities), patient out-of-pocket costs (incontinence pads),
and productivity costs (lost productivity at work and lost time
from work) were all considered. Health-related quality of life
data were collected during the trial via the King’s Health Ques-
tionnaire (KHQ). Using a published algorithm, responses to the
KHQ were transformed into QALYs. The time frame of the
analysis was extended from the 12-week trial period to 52 weeks,
and the total expected costs and the expected QALYs for each
intervention were used in 2-way comparisons. The QALYs
gained were 0.0111, 0.0115, 0.0124, and 0.0143 for TOL, SOL,
FESO 4 mg, and FESO 8 mg, respectively. The overall costs were
£1294, £1344, £1362, and £1424 for FESO 8 mg, SOL, FESO
4 mg, and TOL, respectively. CONCLUSIONS: Economic analy-
ses are used by decision makers in conjunction with clinical and
other information to decide which drug therapy provides the best
economic value. The results of our economic analysis suggest
that FESO may result in fewer overall costs and greater QALYs
gained than treatment with TOL or SOL for the management of
patients with OAB and incontinence.
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OBJECTIVES: Existing projections of the cost of overactive
bladder (OAB) in the United States (US) are incomplete and
outdated. We sought to determine the cost of OAB in the US from
a societal perspective, incorporating direct medical, direct non-
medical, and indirect costs. METHODS: We developed a
prevalence-based model with data on age- and sex-speciﬁc OAB
prevalence, health care utilization, other components of care, and
productivity. Using data from the ﬁvemost recent years of medical
literature, practice guidelines, Medicare and managed care fee
schedules, and expert panel input, we calculated the annual per
capita and total US costs. Direct costs were calculated as the
product of the age/sex-speciﬁc probability that a care component
is used, the age/sex-speciﬁc number of units used, and its unit
price. Indirect costs (lost productivity) were calculated based on
the human capital model and governmental census data. We
applied current age/sex-speciﬁc prevalence rates, treatment pat-
terns, and costs to US census population projections to project
costs of OAB in 2015 and 2020. RESULTS: Mean total annual
per capita cost in 2007 was $1991, comprised of $1500 (direct
medical), $66 (direct non-medical), and $426 (indirect). Given
that about 34 million people in the US have OAB, the total
national cost is $68.2 billion (B) ($51.4B direct medical, $2.3B
direct non-medical, and $14.6B indirect). Mean total annual per
capita costs in 2015 and 2020 would be $2010 and $2036
respectively. Given projections of ~39 million and 42 million
people with OAB in 2015 and 2020, total national costs would be
$78.8B and $85.4B, respectively. CONCLUSIONS: These data
suggest that the economic burden of OAB is about ﬁve-fold higher
than older, non-comprehensive estimates. Inasmuch as 75% of
this cost is for direct medical care, it is important that opportuni-
ties be explored to improve the value of available therapies.
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OBJECTIVES: Chronic kidney disease is a progressive condition
that results in signiﬁcant morbidity and mortality. Dietary
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